Global Joint Pain Injections Market by Injection Type (Corticosteroid Injections, Hyaluronic Acid Injections, Platelet-Rich Plasma (PRP) Injections, Stem Cell Injections), by End-Use Industry (Healthcare and Medical, Hospitals, Clinics), by Application (Osteoarthritis, Rheumatoid Arthritis, Sports Injuries) and By Region: Insights & Forecast (2024 – 2030)

As per Intent Market Research, the Joint Pain Injections Market was valued at USD 6.3 Billion in 2024-e and will surpass USD 11.6 Billion by 2030; growing at a CAGR of 10.7% during 2025 - 2030.

The joint pain injections market is growing steadily due to the increasing prevalence of joint-related conditions such as osteoarthritis, rheumatoid arthritis, and sports injuries. Injections have become a popular method of managing joint pain, offering patients a non-surgical alternative for pain relief and improved mobility. The market encompasses a variety of injection types, including corticosteroids, hyaluronic acid, platelet-rich plasma (PRP), and stem cell injections, each catering to different types of joint issues and patient needs. The demand for joint pain injections is driven by the aging population, rising physical activity levels, and the ongoing advancements in injection-based therapies, which provide targeted and effective treatment for various joint conditions.

Corticosteroid Injections Are Largest Injection Type Owing to Their Immediate Pain Relief

Corticosteroid injections are the largest segment in the joint pain injections market due to their ability to provide immediate and significant pain relief for patients suffering from joint conditions such as osteoarthritis and rheumatoid arthritis. These injections are widely used for reducing inflammation and alleviating pain in the joints, providing temporary relief that can help patients improve mobility and functionality.

Corticosteroid injections are highly effective for managing acute pain, especially in patients who are not yet candidates for surgery or are seeking short-term relief. Due to their established track record and ease of administration, corticosteroid injections remain the most commonly used treatment option for joint pain, thus making them the largest injection type in the market.

Osteoarthritis Is Largest Application Segment Due to High Prevalence and Impact

Osteoarthritis is the largest application segment in the joint pain injections market, driven by its high prevalence and significant impact on patients' quality of life. Osteoarthritis, a degenerative joint disease that leads to the breakdown of cartilage, affects millions of people worldwide, particularly the elderly. This condition often results in chronic pain and stiffness, leading to a substantial demand for effective treatment options, such as joint pain injections, to manage symptoms and improve joint function.

The high demand for injections, especially hyaluronic acid and corticosteroids, in the treatment of osteoarthritis is a key factor contributing to its dominance in the market. These treatments provide relief from pain and inflammation, and are increasingly used as non-surgical alternatives for managing moderate to severe osteoarthritis symptoms. The rising aging population and the increasing burden of osteoarthritis are expected to continue driving growth in this segment.

Healthcare and Medical Is Largest End-Use Industry Due to High Treatment Demand

The healthcare and medical industry is the largest end-use sector in the joint pain injections market due to the increasing demand for joint pain management treatments across various demographics. Healthcare providers, including hospitals, clinics, and specialized pain management centers, administer joint pain injections to patients as a non-surgical solution to alleviate pain and improve mobility. The growing number of people affected by joint-related conditions, coupled with the advancements in injection-based therapies, has led to increased utilization of these injections in healthcare settings.

The convenience, effectiveness, and targeted relief offered by joint pain injections have made them a widely used treatment option in healthcare, contributing to the industry’s dominance in the market. With more patients opting for non-invasive solutions, healthcare providers continue to invest in joint pain injection treatments to meet the rising demand for pain management services.

Platelet-Rich Plasma (PRP) Injections Are Fastest Growing Injection Type Due to Their Regenerative Potential

Platelet-rich plasma (PRP) injections are the fastest growing injection type in the joint pain injections market, driven by their regenerative potential and ability to promote healing in damaged tissues. PRP injections involve the use of the patient's own blood, which is processed to concentrate platelets and growth factors that help stimulate tissue repair and reduce inflammation. This treatment has gained popularity in recent years for managing conditions such as osteoarthritis, sports injuries, and tendonitis, particularly in athletes.

The growing interest in regenerative medicine and the increasing number of clinical studies supporting the efficacy of PRP in promoting tissue regeneration have fueled its rapid growth. As the demand for non-invasive, biologic treatments continues to rise, PRP injections are expected to experience sustained growth in the market, particularly for patients seeking long-term solutions for joint pain and tissue repair.

North America Is Largest Region Owing to High Treatment Adoption and Advanced Healthcare Infrastructure

North America is the largest region in the joint pain injections market, driven by the high adoption of joint pain injection treatments and the region's advanced healthcare infrastructure. The United States, in particular, has a high incidence of joint-related conditions, such as osteoarthritis and rheumatoid arthritis, due to the aging population and lifestyle factors. The region’s healthcare system is well-equipped to provide these advanced therapies, with numerous hospitals, clinics, and specialized centers offering joint pain injection treatments.

The growing demand for non-surgical treatments, along with the increasing number of healthcare providers offering joint pain injections, contributes to North America's dominance in the market. Furthermore, the high level of awareness, access to cutting-edge treatments, and favorable reimbursement policies in the region continue to support the growth of the joint pain injections market.

Competitive Landscape and Key Players

The joint pain injections market is competitive, with several key players driving innovation and development in injection therapies. Companies such as AbbVie, Genzyme (a Sanofi company), Zimmer Biomet, Mitek Sports Medicine, and Regenexx are at the forefront of the market, offering a variety of injection-based treatments for joint pain management. These players are focusing on enhancing the efficacy, safety, and patient experience of their injection therapies, with an emphasis on biologic treatments such as PRP and stem cell injections.

The competitive landscape is shaped by a mix of pharmaceutical companies, medical device manufacturers, and specialized biotech firms. Key strategies include expanding product portfolios, improving treatment outcomes, and entering new regional markets to meet the rising demand for joint pain management. With ongoing research into advanced therapies and regenerative medicine, these companies are expected to continue driving the growth of the joint pain injections market.

Recent Developments:

• Zimmer Biomet launched a new hyaluronic acid-based injection aimed at providing longer-lasting pain relief for knee osteoarthritis patients.
• Abbott Laboratories introduced a new platelet-rich plasma (PRP) injection kit designed to enhance the regenerative treatment of joint injuries.
• Sanofi received FDA approval for its new corticosteroid injection for treating rheumatoid arthritis-related joint inflammation.
• Bioventus expanded its product portfolio with an advanced stem cell injection therapy for joint pain management, offering promising results in clinical trials.
• Medtronic partnered with leading orthopedic centers to conduct a clinical trial evaluating the effectiveness of its latest joint pain injection technology.

List of Leading Companies:

• Zimmer Biomet Holdings, Inc.
• Johnson & Johnson
• Sanofi S.A.
• Abbott Laboratories
• Medtronic Plc
• Bioventus Inc.
• Stryker Corporation
• Regenexx
• Mylan N.V.
• Merck & Co., Inc.
• Ferring Pharmaceuticals
• Anika Therapeutics
• Celltex Therapeutics Corporation
• OrthogenRx, Inc.
• Arthrex, Inc.

Report Scope: